Sagent Pharmaceuticals and Qilu Team Up to Enhance U.S. Access to Injectable Medicines Sagent Pharmaceuticals and Qilu Pharmaceutical join forces to improve U.S. access to critical injectable solutions, addressing significant healthcare needs.

Sagent Pharmaceuticals and Qilu Team Up to Enhance U.S. Access to Injectable Medicines #United_States #Schaumburg #Qilu_Pharmaceutical #Sagent_Pharmaceuticals #Injectable_Products

Minghui Pharmaceutical Partners with Qilu for Oncology Development in Greater China Minghui Pharmaceutical has announced a strategic partnership with Qilu Pharmaceutical to develop the promising B7-H3 ADC therapy across Greater China, highlighting their commitment to cancer innovation.

Minghui Pharmaceutical Partners with Qilu for Oncology Development in Greater China #China #Shanghai #Minghui_Pharmaceutical #Qilu_Pharmaceutical #B7-H3_ADC

Qilu Pharmaceutical Announces Positive Phase Ia Study Results of QLS32015 at ASH 2024 The preliminary results of Qilu Pharmaceutical's Phase Ia study on QLS32015 for multiple myeloma showed promising anti-tumor activity and tolerability.

Qilu Pharmaceutical Announces Positive Phase Ia Study Results of QLS32015 at ASH 2024 #China #Jinan #ASH_2024 #Qilu_Pharmaceutical #QLS32015